Inhibition of angiogenesis by the antifungal drug itraconazole.

Angiogenesis, the formation of new blood vessels, is implicated in a number of important human diseases, including cancer, diabetic retinopathy, and rheumatoid arthritis. To identify clinically useful angiogenesis inhibitors, we assembled and screened a library of mostly Food and Drug Administration-approved drugs for inhibitors of human endothelial cell proliferation. One of the most promising and unexpected hits was itraconazole, a known antifungal drug. Itraconazole inhibits endothelial cell cycle progression at the G1 phase in vitro and blocks vascular endothelial growth factor/basic fibroblast growth factor-dependent angiogenesis in vivo. In attempts to delineate the mechanism of action of itraconazole, we found that human lanosterol 14alpha-demethylase (14DM) is essential for endothelial cell proliferation and may partially mediate the inhibition of endothelial cells by itraconazole. Together, these findings suggest that itraconazole has the potential to serve as an antiangiogenic drug and that lanosterol 14DM is a promising new target for discovering new angiogenesis inhibitors.

[1]  W. Völkel,et al.  Comparison of lanosterol-14 alpha-demethylase (CYP51) of human and Candida albicans for inhibition by different antifungal azoles. , 2006, Toxicology.

[2]  R. Kerbel.  Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.

[3]  Jun O. Liu,et al.  Identification of type 1 inosine monophosphate dehydrogenase as an antiangiogenic drug target. , 2006, Journal of medicinal chemistry.

[4]  W. L. Nelson,et al.  STEREOCHEMICAL ASPECTS OF ITRACONAZOLE METABOLISM IN VITRO AND IN VIVO , 2006, Drug Metabolism and Disposition.

[5]  Bryan L. Roth,et al.  Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery , 2005, Nature Reviews Drug Discovery.

[6]  Jun O. Liu,et al.  Calmodulin‐dependent protein kinase IV regulates nuclear export of Cabin1 during T‐cell activation , 2005, The EMBO journal.

[7]  D. V. Lapka,et al.  Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer. , 2005, Clinical journal of oncology nursing.

[8]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[9]  D. Gómez-Coronado,et al.  Cholesterol is essential for mitosis progression and its deficiency induces polyploid cell formation. , 2004, Experimental cell research.

[10]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[11]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[12]  P. Opolon,et al.  Cerivastatin, an Inhibitor of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase, Inhibits Endothelial Cell Proliferation Induced by Angiogenic Factors In Vitro and Angiogenesis in In Vivo Models , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[13]  C. Heeschen,et al.  Statins Have Biphasic Effects on Angiogenesis , 2002, Circulation.

[14]  G. Koehl,et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.

[15]  E. Levin,et al.  Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.

[16]  D. Gómez-Coronado,et al.  Cholesterol starvation decreases P34cdc2 kinase activity and arrests the cell cycle at G2 , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  D. Kelly,et al.  Characteristics of the heterologously expressed human lanosterol 14α‐demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candida albicans CYP51 with azole antifungal agents , 1999, Yeast.

[18]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[19]  W. Bornmann,et al.  The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Biemann,et al.  Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. , 1997, Chemistry & biology.

[21]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[22]  R. Heller,et al.  Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterol-lowering activity , 1995 .

[23]  D. Swinney,et al.  Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo. , 1994, Biochemistry.

[24]  A. Passaniti,et al.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. , 1992, Laboratory investigation; a journal of technical methods and pathology.

[25]  D. Ingber,et al.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth , 1990, Nature.

[26]  P. Marichal,et al.  Biochemical basis for the activity and selectivity of oral antifungal drugs. , 1990, British journal of clinical practice. Supplement.

[27]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[28]  J. Lawlis,et al.  Fumagillin (H-3), a new antibiotic with amebicidal properties. , 1951, Science.